Related Experiment Video
Updated: Jul 18, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
AMPK activation coupling SENP1-Sirt3 axis protects against acute kidney injury
Minyan Zhu1, Jianli He2, Yao Xu1
1Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201207, China.
Abstract:
Acute kidney injury (AKI) is a critical clinical condition that causes kidney fibrosis, and it currently lacks specific treatment options. In this research, we investigate the role of the SENP1-Sirt3 signaling pathway and its correlation with mitochondrial dysfunction in proximal tubular epithelial cells (PTECs) using folic acid (FA) and ischemia-reperfusion-induced (IRI) AKI models. Our findings reveal that Sirt3 SUMOylation site mutation (Sirt3 KR) or pharmacological stimulation (metformin) protected mice against AKI and subsequent kidney inflammation and fibrosis by decreasing the acetylation level of mitochondrial SOD2, reducing mitochondrial reactive oxygen species (mtROS), and subsequently restoring mitochondrial ATP level, reversing mitochondrial morphology and alleviating cell apoptosis. In addition, AKI in mice was similarly alleviated by reducing mtROS levels using N-acetyl-L-cysteine (NAC) or MitoQ. Metabolomics analysis further demonstrated an increase in antioxidants and metabolic shifts in Sirt3 KR mice during AKI, compared with Sirt3 wild-type (WT) mice. Activation of the AMPK pathway using metformin promoted the SENP1-Sirt3 axis and protected PTECs from apoptosis. Hence, the augmented deSUMOylation of Sirt3 in mitochondria, activated through the metabolism-related AMPK pathway, protects against AKI and subsequently mitigated renal inflammation and fibrosis through Sirt3-SOD2-mtROS, which represents a potential therapeutic target for AKI.
Insights
Targeting the SENP1-Sirt3 pathway protects against acute kidney injury (AKI) and subsequent fibrosis. Activating this axis reduces mitochondrial damage and inflammation, offering a potential therapeutic strategy for kidney disease.
Area of Science:
- Nephrology
- Mitochondrial Biology
- Molecular Signaling
Background:
- Acute kidney injury (AKI) is a significant clinical issue leading to kidney fibrosis with limited treatments.
- Mitochondrial dysfunction in proximal tubular epithelial cells (PTECs) plays a crucial role in AKI pathogenesis.
- The SENP1-Sirt3 signaling pathway's role in AKI requires further investigation.
Purpose of the Study:
- To investigate the role of the SENP1-Sirt3 signaling pathway in AKI.
- To explore the correlation between this pathway and mitochondrial dysfunction in PTECs.
- To identify potential therapeutic targets for AKI-induced kidney fibrosis.
Main Methods:
- Utilized folic acid (FA) and ischemia-reperfusion-induced (IRI) AKI mouse models.
- Investigated Sirt3 SUMOylation site mutation (Sirt3 KR) and pharmacological stimulation (metformin, NAC, MitoQ).
- Performed metabolomics analysis and assessed mitochondrial function, oxidative stress, and apoptosis markers.
Main Results:
- Sirt3 KR mutation or metformin treatment protected against AKI, inflammation, and fibrosis.
- These interventions reduced mitochondrial acetylation of SOD2, decreased mitochondrial reactive oxygen species (mtROS), and restored ATP levels.
- Metformin activated the AMPK pathway, promoting the SENP1-Sirt3 axis and protecting PTECs.
Conclusions:
- Augmented mitochondrial deSUMOylation of Sirt3, via the AMPK pathway, protects against AKI.
- The Sirt3-SOD2-mtROS axis is a key mediator in mitigating renal inflammation and fibrosis.
- Targeting the SENP1-Sirt3 pathway presents a promising therapeutic strategy for AKI.
More Related Videos
Related Concept Videos
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
PI3K/mTOR/AKT Signaling Pathway
Acute Kidney Injury I: Introduction
cAMP-dependent Protein Kinase Pathways
Acute Kidney Injury V: Interprofessional Care

